EpiPen® Auto-Injectors — Net Sales
Viatris EpiPen® Auto-Injectors — Net Sales increased by 28.0% to $101.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.6%, from $96.70M to $101.10M. Over 4 years (FY 2021 to FY 2025), EpiPen® Auto-Injectors — Net Sales shows an upward trend with a 4.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market demand, successful brand loyalty, or effective pricing strategies, while a decrease may signal increased generic competition, loss of market share, or supply chain constraints.
Detailed definition
This metric represents the total revenue generated from the sale of epinephrine auto-injector devices, net of returns, a...
Peer comparison
Comparable to revenue metrics for specific branded specialty drugs or legacy medical devices at other pharmaceutical companies, often evaluated against the backdrop of patent cliffs and generic entry.
vtrs_segment_epipen_auto_injectors_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.10M | $129.50M | $54.40M | $88.80M | $106.50M | $114.40M | $68.30M | $95.80M | $127.50M | $131.90M | $87.00M | $80.20M | $115.50M | $123.20M | $73.10M | $96.70M | $136.80M | $157.20M | $79.00M | $101.10M |
| QoQ Change | — | +24.4% | -58.0% | +63.2% | +19.9% | +7.4% | -40.3% | +40.3% | +33.1% | +3.5% | -34.0% | -7.8% | +44.0% | +6.7% | -40.7% | +32.3% | +41.5% | +14.9% | -49.7% | +28.0% |
| YoY Change | — | — | — | — | +2.3% | -11.7% | +25.6% | +7.9% | +19.7% | +15.3% | +27.4% | -16.3% | -9.4% | -6.6% | -16.0% | +20.6% | +18.4% | +27.6% | +8.1% | +4.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's epipen® auto-injectors — net sales?
- Viatris (VTRS) reported epipen® auto-injectors — net sales of $101.10M in Q1 2026.
- How has Viatris's epipen® auto-injectors — net sales changed year-over-year?
- Viatris's epipen® auto-injectors — net sales increased by 4.6% year-over-year, from $96.70M to $101.10M.
- What is the long-term trend for Viatris's epipen® auto-injectors — net sales?
- Over 4 years (2021 to 2025), Viatris's epipen® auto-injectors — net sales has grown at a 4.6% compound annual growth rate (CAGR), from $391.70M to $469.70M.
- What does epipen® auto-injectors — net sales mean?
- The total revenue earned from selling EpiPen auto-injectors after accounting for discounts and returns.